Terms: = Prostate cancer AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551 AND Treatment
56 results:
1. Novel estrogen receptor β/histone deacetylase dual-targeted near-infrared fluorescent probes as theranostic agents for imaging and treatment of prostate cancer.
He P; Yu H; Deng X; Xin L; Xu B; Zhou HB; Dong C
Eur J Med Chem; 2024 Mar; 268():116236. PubMed ID: 38367494
[TBL] [Abstract] [Full Text] [Related]
2. Impact of inter-observer variability on first axillary level dosimetry in breast cancer radiotherapy: An AIRO multi-institutional study.
Leonardi MC; Pepa M; Zaffaroni M; Vincini MG; Luraschi R; Vigorito S; Morra A; Dicuonzo S; Mazzola GC; Gerardi MA; Zerella MA; Cante D; Petrucci E; Borzì G; Marrocco M; Chieregato M; Iadanza L; Lobefalo F; Valenti M; Cavallo A; Russo S; Guernieri M; Malatesta T; Meaglia I; Liotta M; Palumbo I; Marcantonini M; Mezzenga E; Falivene S; Arrichiello C; Barbero MP; Ivaldi GB; Catalano G; Vidali C; Giannitto C; Ciabattoni A; Meattini I; Aristei C; Orecchia R; Cattani F; Jereczek-Fossa BA
Tumori; 2023 Dec; 109(6):570-575. PubMed ID: 37688419
[TBL] [Abstract] [Full Text] [Related]
3. Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer.
Celada SI; Li G; Celada LJ; Lu W; Kanagasabai T; Feng W; Cao Z; Salsabeel N; Mao N; Brown LK; Mark ZA; Izban MG; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Wang X; Chen Z
Mol Oncol; 2023 Oct; 17(10):2126-2146. PubMed ID: 37491794
[TBL] [Abstract] [Full Text] [Related]
4. Expression and Therapeutic Targeting of TROP-2 in treatment-Resistant prostate cancer.
Sperger JM; Helzer KT; Stahlfeld CN; Jiang D; Singh A; Kaufmann KR; Niles DJ; Heninger E; Rydzewski NR; Wang L; Wang L; Yang R; Ren Y; Engle JW; Huang P; Kyriakopoulos CE; Slovin SF; Soule HR; Zhao SG; Kohli M; Tagawa ST; Cai W; Dehm SM; Lang JM
Clin Cancer Res; 2023 Jun; 29(12):2324-2335. PubMed ID: 36939530
[TBL] [Abstract] [Full Text] [Related]
5. Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in prostate cancer by Low-Intensity Focused Ultrasound.
Dai J; Wu Y; Chen Z; Xiao L; Zhang W; Cao Y
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614265
[TBL] [Abstract] [Full Text] [Related]
6. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Merseburger AS; Attard G; Åström L; Matveev VB; Bracarda S; Esen A; Feyerabend S; Senkus E; López-Brea Piqueras M; Boysen G; Gourgioti G; Martins K; Chowdhury S
Lancet Oncol; 2022 Nov; 23(11):1398-1408. PubMed ID: 36265504
[TBL] [Abstract] [Full Text] [Related]
7. The Effectiveness of prostate Imaging and Reporting and Data System Version 2 in the Diagnosis of prostate cancer with Screening Parameters Correlation.
Arik ŞB; Güvenir D; Bozlar U; Taşar M; Turgut B
Arch Esp Urol; 2022 Jun; 75(5):416-422. PubMed ID: 35983812
[TBL] [Abstract] [Full Text] [Related]
8. Estrogen receptor β-targeted hypoxia-responsive near-infrared fluorescence probes for prostate cancer study.
Xie B; Meng Q; Yu H; Shen K; Cheng Y; Dong C; Zhou HB
Eur J Med Chem; 2022 Aug; 238():114506. PubMed ID: 35671592
[TBL] [Abstract] [Full Text] [Related]
9. GRP78-targeted and doxorubicin-loaded nanodroplets combined with ultrasound: a potential novel theranostics for castration-resistant prostate cancer.
Zhao Y; Shi D; Shang M; Sun X; Guo L; Meng D; Liu X; Zhou X; Li J
Drug Deliv; 2022 Dec; 29(1):203-213. PubMed ID: 34985396
[TBL] [Abstract] [Full Text] [Related]
10. PSMA-targeted melanin-like nanoparticles as a multifunctional nanoplatform for prostate cancer theranostics.
Dai L; Shen G; Wang Y; Yang P; Wang H; Liu Z
J Mater Chem B; 2021 Jan; 9(4):1151-1161. PubMed ID: 33434248
[TBL] [Abstract] [Full Text] [Related]
11. Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from α-amino acid with (S)- or (R)-configuration at P1' region.
Kwon H; Lim H; Ha H; Choi D; Son SH; Nam H; Minn I; Byun Y
Bioorg Chem; 2020 Nov; 104():104304. PubMed ID: 33011530
[TBL] [Abstract] [Full Text] [Related]
12. Mixed-beam approach for high-risk prostate cancer: Carbon-ion boost followed by photon intensity-modulated radiotherapy. Dosimetric and geometric evaluations (AIRC IG-14300).
Gugliandolo SG; Marvaso G; Comi S; Pepa M; Romanò C; Zerini D; Augugliaro M; Russo S; Vischioni B; Valvo F; Giandini T; Avuzzi B; Valdagni R; Ciardo D; De Cobelli O; Jereczek-Fossa BA; Cattani F; Orecchia R
Phys Med; 2020 Aug; 76():327-336. PubMed ID: 32750548
[TBL] [Abstract] [Full Text] [Related]
13. Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice.
Sanmamed N; Glicksman RM; Herrera-Caceres J; Lehrer EJ; Heaton J; Hansen AR; Chung P; Fleshner NE; Den RB; Zaorsky NG; Berlin A
Urol Oncol; 2020 Nov; 38(11):848.e1-848.e7. PubMed ID: 32553790
[TBL] [Abstract] [Full Text] [Related]
14. Long intergenic noncoding RNA 00844 promotes apoptosis and represses proliferation of prostate cancer cells through upregulating GSTP1 by recruiting EBF1.
Qiu K; Zheng Z; Huang Y
J Cell Physiol; 2020 Nov; 235(11):8472-8485. PubMed ID: 32329523
[TBL] [Abstract] [Full Text] [Related]
15. Carcinosarcoma of the prostate: case report with molecular and histological characterization.
Salvi S; Casadio V; Martignano F; Gurioli G; Tumedei MM; Calistri D; Gunelli R; Costantini M
Int J Biol Markers; 2018 Nov; 33(4):540-544. PubMed ID: 30101629
[TBL] [Abstract] [Full Text] [Related]
16. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study.
Coughlin GD; Yaxley JW; Chambers SK; Occhipinti S; Samaratunga H; Zajdlewicz L; Teloken P; Dunglison N; Williams S; Lavin MF; Gardiner RA
Lancet Oncol; 2018 Aug; 19(8):1051-1060. PubMed ID: 30017351
[TBL] [Abstract] [Full Text] [Related]
17. To prep or not to prep - that is the question: A randomized trial on the use of antiflatulent medication as part of bowel preparation for patients having image guided external beam radiation therapy to the prostate.
McGuffin M; Devji N; Kehoe L; Carty A; Russell S; Di Prospero L; DeAngelis C; Kiss A; Vesprini D; Loblaw A; D'Alimonte L
Pract Radiat Oncol; 2018; 8(2):116-122. PubMed ID: 29329996
[TBL] [Abstract] [Full Text] [Related]
18. Noninvasive Ablation of prostate cancer Spheroids Using Acoustically-Activated Nanodroplets.
Aydin O; Vlaisavljevich E; Yuksel Durmaz Y; Xu Z; ElSayed ME
Mol Pharm; 2016 Dec; 13(12):4054-4065. PubMed ID: 27696857
[TBL] [Abstract] [Full Text] [Related]
19. Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.
Michaelsen FW; Saeed ME; Schwarzkopf J; Efferth T
Phytomedicine; 2015 Dec; 22(14):1223-31. PubMed ID: 26655404
[TBL] [Abstract] [Full Text] [Related]
20. Distinct promoters, subjected to epigenetic regulation, drive the expression of two clusterin mRNAs in prostate cancer cells.
Bonacini M; Coletta M; Ramazzina I; Naponelli V; Modernelli A; Davalli P; Bettuzzi S; Rizzi F
Biochim Biophys Acta; 2015 Jan; 1849(1):44-54. PubMed ID: 25464035
[TBL] [Abstract] [Full Text] [Related]
[Next]
